Hossein Tabatabaeian

Dr. Hossein Tabatabaeian

Cancer research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ARAlisha Ramos
Alisha Ramos
SSsamira sadeghi
samira sadeghi
HTHossein Tabatabaeian
Hossein Tabatabaeian
With nearly 10 million deaths, cancer is the leading cause of mortality worldwide. Along with major key parameters that control cancer treatment management, such as diagnosis, resistance to the classical and new chemotherapeutic reagents continues to be a significant problem. Intrinsic or acquired chemoresistance leads to cancer recurrence in many cases that eventually causes failure in the successful treatment and death of cancer patients. Various determinants, including tumor heterogeneity and tumor microenvironment, could cause chemoresistance through a diverse range of mechanisms. In this review, we summarize the key determinants and the underlying mechanisms by which chemoresistance appears. We then describe which strategies have been implemented and studied to combat such a lethal phenomenon in the management of cancer treatment, with emphasis on the need to improve the early diagnosis of cancer complemented by combination therapy.

11 May 2020 in Oncogene
Verified
Journal Article
Open access
PDF file
HTHossein Tabatabaeian
Hossein Tabatabaeian
ARAngad Rao
Angad Rao
ARAlisha Ramos
Alisha Ramos
TCTinghine Chu
Tinghine Chu
MSMarius Sudol
Marius Sudol
YLYoon Pin Lim
Yoon Pin Lim
WW domain-binding protein 2 (WBP2) is an emerging oncoprotein. Over the past decade, WBP2 surfaced as a key node connecting key signaling pathways associated with ER/PR, EGFR, PI3K, Hippo, and Wnt in cancer. In addition to the oncogenic functions of WBP2, this review discusses the latest research regarding the multilevel regulation and modes of action of WBP2 and how they can be exploited for molecular medicine. In translational research, evidence supports the role of WBP2 as a biomarker for early detection, prognosis, and companion diagnostics in breast cancer. Finally, we envision new trends in WBP2 research in the space of molecular etiology of cancer, targeted therapeutics, and precision medicine.

22 February 2017 in Journal of Genetics
Verified
Journal Article
Closed access
PDF file
SSSamira Sadeghi
Samira Sadeghi
ZHZohreh Hojati
Zohreh Hojati
HTHossein Tabatabaeian
Hossein Tabatabaeian

Verified
Journal Article
Open access
PDF file
HBHamed Bashiri
Hamed Bashiri
HTHossein Tabatabaeian
Hossein Tabatabaeian
Multiple myeloma (MM) is the second most prevalent hematologic malignancy. In the past few years, the survival of MM patients has increased due to the emergence of novel drugs and combination therapies. Nevertheless, one of the significant obstacles in treating most MM patients is drug resistance, especially for individuals who have experienced relapses or developed resistance to such cutting-edge treatments. One of the critical processes in developing drug resistance in MM is autophagic activity, an intracellular self-digestive process. Several possible strategies of autophagy involvement in the induction of MM-drug resistance have been demonstrated thus far. In multiple myeloma, it has been shown that High mobility group box protein 1 (HMGB1)-dependent autophagy can contribute to drug resistance. Moreover, activation of autophagy via proteasome suppression induces drug resistance. Additionally, the effectiveness of clarithromycin as a supplemental drug in treating MM has been reported recently, in which autophagy blockage is proposed as one of the potential action mechanisms of CAM. Thus, a promising therapeutic approach that targets autophagy to trigger the death of MM cells and improve drug susceptibility could be considered. In this review, autophagy has been addressed as a survival strategy crucial for drug resistance in MM.

4 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HTHossein Tabatabaeian
Hossein Tabatabaeian
SPSamantha Yang Peiling
Samantha Yang Peiling
Yvonne TayYvonne Tay
Yvonne Tay
Thyroid cancer is the most prevalent malignancy of the endocrine system and the ninth most common cancer globally. Despite the advances in the management of thyroid cancer, there are critical issues with the diagnosis and treatment of thyroid cancer that result in the poor overall survival of undifferentiated and metastatic thyroid cancer patients. Recent studies have revealed the role of different non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) that are dysregulated during thyroid cancer development or the acquisition of resistance to therapeutics, and may play key roles in treatment failure and poor prognosis of the thyroid cancer patients. Here, we systematically review the emerging roles and molecular mechanisms of ncRNAs that regulate thyroid tumorigenesis and drug response. We then propose the potential clinical implications of ncRNAs as novel diagnostic and prognostic biomarkers for thyroid cancer.

3 September 2020 in Human Cell
Verified
Journal Article
Closed access
PDF file
NDNasrin Fattahi Dolatabadi
Nasrin Fattahi Dolatabadi
ADArezo Dehghani
Arezo Dehghani
ESElham Shahand
Elham Shahand
MYMohammadreza Yazdanshenas
Mohammadreza Yazdanshenas
HTHossein Tabatabaeian
Hossein Tabatabaeian
KGKamran Ghaedi
Kamran Ghaedi